Literature DB >> 31620844

The new international neuroblastoma response criteria.

Katharine E Orr1,2, Kieran McHugh3.   

Abstract

Over recent years significant advances in histopathology and functional imaging techniques for the diagnosis and restaging of children with neuroblastoma have led to better quantification of disease and assessment of disease response, allowing for better treatment stratification. In this review we summarise recent changes to the International Neuroblastoma Response Criteria including the use of RECIST (Response Evaluation Criteria in Solid Tumours) guidance for measurable soft-tissue disease, replacement of technetium-99 m-methylene diphosphonate (MDP) bone scans with metaiodobenzylguanidine (MIBG) scan or [F-18]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET)/CT scanning, and a new category of minimal residual bone marrow disease.

Entities:  

Keywords:  Children; Magnetic resonance imaging; Metaiodobenzylguanidine scan; Neuroblastoma; Positron emission tomography; Staging

Year:  2019        PMID： 31620844     DOI： 10.1007/s00247-019-04397-2

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN： 0301-0449


  14 in total

1.  Whole-body MRI of neuroblastoma.

Authors:  Hyun Woo Goo
Journal:  Eur J Radiol       Date:  2009-09-24       Impact factor: 3.528

2.  Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group.

Authors:  Giovanni Cecchetto; Veronique Mosseri; Bruno De Bernardi; Pierre Helardot; Tom Monclair; Elisa Costa; Ernst Horcher; Sylvia Neuenschwander; Paolo Tomà; Antonino Rizzo; Jean Michon; Keith Holmes
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

3.  Guidelines on nuclear medicine imaging in neuroblastoma.

Authors:  Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10       Impact factor: 9.236

4.  Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study.

Authors:  Rochelle Bagatell; Kieran McHugh; Arlene Naranjo; Collin Van Ryn; Chaim Kirby; Penelope Brock; Karen A Lyons; Lisa J States; Yesenia Rojas; Alexandra Miller; Sam L Volchenboum; Thorsten Simon; Barbara Krug; Sabine Sarnacki; Dominique Valteau-Couanet; Dietrich von Schweinitz; Birgit Kammer; Claudio Granata; Luca Pio; Julie R Park; Jed Nuchtern
Journal:  J Clin Oncol       Date:  2016-01-11       Impact factor: 44.544

5.  International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.

Authors:  G M Brodeur; R C Seeger; A Barrett; F Berthold; R P Castleberry; G D'Angio; B De Bernardi; A E Evans; M Favrot; A I Freeman
Journal:  J Clin Oncol       Date:  1988-12       Impact factor: 44.544

Review 6.  Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Julie R Park; Rochelle Bagatell; Susan L Cohn; Andrew D Pearson; Judith G Villablanca; Frank Berthold; Susan Burchill; Ariane Boubaker; Kieran McHugh; Jed G Nuchtern; Wendy B London; Nita L Seibel; O Wolf Lindwasser; John M Maris; Penelope Brock; Gudrun Schleiermacher; Ruth Ladenstein; Katherine K Matthay; Dominique Valteau-Couanet
Journal:  J Clin Oncol       Date:  2017-05-04       Impact factor: 44.544

7.  Plasma glucose and insulin, urinary catecholamine and cortisol responses to test breakfasts with high or low fibre content: the importance of the previous diet.

Authors:  I B Sundell; G Hallmans; T K Nilsson; C Nygren
Journal:  Ann Nutr Metab       Date:  1989       Impact factor: 3.374

Review 8.  Nuclear medicine and multimodality imaging of pediatric neuroblastoma.

Authors:  Wolfgang Peter Mueller; Eva Coppenrath; Thomas Pfluger
Journal:  Pediatr Radiol       Date:  2012-11-14

9.  The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.

Authors:  Tom Monclair; Garrett M Brodeur; Peter F Ambros; Hervé J Brisse; Giovanni Cecchetto; Keith Holmes; Michio Kaneko; Wendy B London; Katherine K Matthay; Jed G Nuchtern; Dietrich von Schweinitz; Thorsten Simon; Susan L Cohn; Andrew D J Pearson
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

10.  123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel.

Authors:  V Lewington; B Lambert; U Poetschger; Z Bar Sever; F Giammarile; A J B McEwan; Rita Castellani; T Lynch; B Shulkin; M Drobics; A Staudenherz; R Ladenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-09-24       Impact factor: 9.236
View more
  3 in total

1.  CT-Based Radiomics Signature With Machine Learning Predicts MYCN Amplification in Pediatric Abdominal Neuroblastoma.

Authors:  Xin Chen; Haoru Wang; Kaiping Huang; Huan Liu; Hao Ding; Li Zhang; Ting Zhang; Wenqing Yu; Ling He
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

2.  Prediction for Mitosis-Karyorrhexis Index Status of Pediatric Neuroblastoma via Machine Learning Based 18F-FDG PET/CT Radiomics.

Authors:  Lijuan Feng; Luodan Qian; Shen Yang; Qinghua Ren; Shuxin Zhang; Hong Qin; Wei Wang; Chao Wang; Hui Zhang; Jigang Yang
Journal:  Diagnostics (Basel)       Date:  2022-01-20

3.  ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.

Authors:  James I Geller; Joseph G Pressey; Malcolm A Smith; Rachel A Kudgus; Mariana Cajaiba; Joel M Reid; David Hall; Donald A Barkauskas; Stephen D Voss; Steve Y Cho; Stacey L Berg; Jeffrey S Dome; Elizabeth Fox; Brenda J Weigel
Journal:  Cancer       Date:  2020-09-11       Impact factor: 6.860
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.